Diethrich E B
Arizona Heart Institute, Phoenix 85006, USA.
Tex Heart Inst J. 1998;25(1):10-6.
The exclusion of abdominal aortic aneurysms with endoluminal grafts has generated a great deal of interest since the early 1990s, and many centers are currently evaluating the procedure and comparing it to classic surgical exclusion. Although endoluminal grafting procedures show promise, development and clinical testing of devices is a time-consuming process that is influenced greatly by the regulatory climate in the country where the clinical trials take place. Nevertheless, a number of devices are currently under study, and the advantages of 2nd- and 3rd-generation technology are reflected in reduced rates of complications such as endoleaks and thrombosis. Further study will be required to perfect these devices and observe their long-term success in the exclusion of abdominal aortic aneurysms.
自20世纪90年代初以来，腔内移植物治疗腹主动脉瘤受到了广泛关注，目前许多中心正在评估该手术，并将其与传统外科手术进行比较。尽管腔内移植手术前景广阔，但器械的研发和临床试验是一个耗时的过程，很大程度上受到开展临床试验国家监管环境的影响。尽管如此，目前仍有多种器械在研究中，第二代和第三代技术的优势体现在诸如内漏和血栓形成等并发症发生率的降低。还需要进一步研究来完善这些器械，并观察其在治疗腹主动脉瘤方面的长期疗效。
